Recent news on Prialt

Nurture local scientists for economic growth  -  May 6, 2007
ABS CBN News,Filipino scientists Dr. Baldomero Olivera and Dr. Lourdes Cruz were the first to study prialt ziconotide, a pain killer 1000 times more powerful than

Elan drops 7pc on higher Q1 loss, Tysabri sales  -  Apr 24, 2007
Irish Independent,...of $33.3ma year earlier when the company benefited from a once-off gain of $44.2m related to the sale of European rights to the Prialt pain relief drug.

UPDATE 1-Elan Q1 loss doubled but MS drug keeps on track  -  Apr 24, 2007
Reuters...of debt this quarter and the inclusion of a gain on the sale of EU rights to Prialt in 2006," Chief Financial Officer Shane Cooke said in a statement.

Daily Briefing  -  Apr 24, 2007
Atlanta Journal Constitution (subscription),...exceptional factors: the 2007 repayment of $18.8 million in debt vs. a $44.2 million gain from the 2006 sale of rights to the chronic pain drug Prialt.

Harnessing the therapeutic power of venom  -  Apr 12, 2007
BiopharmaReporter.com,It developed Prialt (ziconotide), a non-opioid pain killer that blocks N-type calcium channels. The drug is a synthetic version of a peptide found in cone

HPU looks for cures in sea life  -  27 Mar 2007
Honolulu Star-Bulletin,For example, he said, painkillers morphine and codeine were developed from the opium plant, and Prialt, a chemotherapy drug, came from chemical toxins

Consensus Panel Issues New Guidelines For Pain Management Via  -  Mar 15, 2007
Pharmaceutical Online (press release),The new algorithm includes ziconotide (PRIALT, Elan Corp.) as an alternative to first-line opioids, morphine and hydromorphone and as a second-line

Tysabri forecast to drive Elan's return to profitability  -  Feb 21, 2007
Pharma Times (subscription),Severe pain treatment Prialt (ziconotide) brought in $3.4 million, up 70%, but the main growth drivers were Elan's manufacturing revenue and royalties,

Elan Reports Fourth Quarter and Full-Year 2006 Financial Results  -  Feb 19, 2007
American Digital Networks (press release),Prialt was launched in the US market during the first quarter of 2005. For the full-year 2006, revenue from Prialt increased to $12.1 million from $6.3

Elan quarterly loss narrows, sees return to profit  -  Feb 20, 2007
MarketWatchElan continues to focus on reducing costs, while focusing on its key products such as pain drug Prialt, anti-infective drugs Maximpime and Azactam,

Elan's Q4 Net Loss Narrows; Revenue Up 19%; Expects Breakeven By ...  -  Feb 20, 2007
Trading Markets,Maxipime sales added $46.2 million, antibiotic injection Azactam sales supplied $21.3 million and pain killer Prialt contributed $3.4 million.

US snail venom is a better pain killer: Doctor  -  Feb 19, 2007
Hindustan Times,He said the drug was being developed from Cone snail “Prialt�, which is largely available in the USA and its compound (XEN- 2174) to be 1000 times more

Big dispute over tiny root  -  Feb 14, 2007
Chicago Daily Herald,The venom of a deadly sea snail found off the coast of the Philippines led Elan Pharmaceuticals Inc. to develop the painkiller Prialt, which US regulators

Polyanalgesic Consensus Panel Issues New Guidelines for Pain ...  -  Feb 8, 2007
American Digital Networks (press release),The new algorithm includes ziconotide (PRIALT, Elan Corp.) as an alternative to first-line opioids, morphine and hydromorphone and as a second-line

Peruvian root in bioprospecting dispute  -  Jan 5, 2007
MLive.com,The venom of a deadly sea snail found off the coast of the Philippines led Elan Pharmaceuticals Inc. to develop the painkiller Prialt, which US regulators

Beating Pain at a Snail’s Pace  -  Dec 21, 2006
13WHAM-TV,Recently, Dr. Hammam Akbik gave Waller an injection of a medication called Prialt that was initially discovered in snail venom.

POWER PLANT  -  Jan 6, 2007
Miami Herald,The venom of a deadly sea snail found off the coast of the Philippines led Elan Pharmaceuticals to develop the painkiller Prialt, which US regulators

Beating Pain at a Snail’s Pace  -  Dec 21, 2006
13WHAM-TV,Recently, Dr. Hammam Akbik gave Waller an injection of a medication called Prialt that was initially discovered in snail venom.

Snail venom probed for pain treatment  -  Dec 14, 2006
Carlsbad Current Argus,The new substance could one day be found in pharmacies next to other cone snail-inspired compounds, such as Prialt, a pain-relief treatment for terminal

Public Nuisances  Oct 26, 2006
...and moves from unwarranted alarm about a painkiller to Great Expectations about another, newer painkiller, one that sounds grisly to me, something called Prialt ... -Human Events, Elan Q3 Loss Widens, Revenues Decline On Maxipime Supply Shortages ...  Oct 25, 2006
Third quarter revenue from Prialt, launched in the US market during the first quarter of 2005, for the third quarter was $3.1 million, compared to $1.5 million ... -Trading Markets, Venomous Cone Snail Biologist Named To Institute Of Medicine  Oct 11, 2006
The natural form of Prialt - a new drug for severe pain approved in 2004 by the US Food and Drug Administration - was discovered in Olivera's lab in 1979 by J ... -Medical News Today (press release), U. biologist honored for drug research  Oct 9, 2006
The natural form of Prialt — a drug for severe pain approved in 2004 by the US Food and Drug Administration — was discovered in Olivera's lab in 1979 by J ... -Deseret News, Snail Toxin May Spur New Meds Against Brain Disease  Aug 26, 2006
...same University of Utah researcher who - as an incoming freshman student in 1979 - discovered another “conotoxin� that was developed into Prialt, a drug ... -Medical News Today

Snails may aid relief of pain  -  Nov 13, 2006
Salt Lake Tribune,The new substance could one day be found in pharmacies next to other cone snail-inspired compounds, such as Prialt, a pain relief treatment for terminal

Snail poison, pain relief?  -  Nov 21, 2006
Richmond Times Dispatch,Previously, McIntosh was involved in research that led to development of Prialt, a pain treatment also based on cone snail toxins that is injected into

Eisai Announces Establishment of New Pharmaceuticals Marketing ...  -  Nov 21, 2006
PharmaLive.com (press release),...from European Committee for Medicinal Products for Human Use on November 16, 2006), as well as the non-opioid severe chronic pain agent Prialt®.

Snail venom might help treat nerve pain  -  Nov 20, 2006
HeraldNet,Previously, McIntosh was involved in research that led to the development of Prialt, a pain treatment also based on cone snail toxins that is injected into

Snail toxins reveal novel way to fight severe nerve pain  -  Nov 16, 2006
PressZoom (press release),It is Prialt, which must be injected into fluid surrounding the spinal cord as a treatment for severe pain due to cancer, AIDS, injury, failed back surgery

Venomous snails could root out nerve pain  -  Nov 13, 2006
Globe and Mail,Previously, Dr. McIntosh was involved in research that led to development of Prialt, a pain treatment also based on cone snail toxins that is injected into

Snail venom painkiller launched  Jul 10, 2006
Britain. Prialt is a strong painkiller designed for patients suffering from chronic pain who cannot tolerate treatments like morphine. ... -BBC News

Eisai launches snail venom pain drug in Britain  Jul 9, 2006
Japanese drugmaker Eisai Co Ltd, which acquired European rights to Prialt from Ireland's Elan Corp Plc, is marketing the medicine first in Britain before ... -Reuters

Eisai launches snail venom pain drug in Britain  Jul 9, 2006
Japanese drugmaker Eisai Co Ltd (4523.T: Quote, Profile, Research), which acquired European rights to Prialt from Ireland's Elan Corp Plc (ELN.I: Quote, Profile ... -Reuters

Painkiller Based on Sea Snail Venom Made Available in Britain  Jul 11, 2006
New painkiller, Prialt, based on the venom of a sea snail will be available in Britain from today. The drug Prialt, or ziconotide ... -MedIndia

Japan's Eisai Launches 'Sea Snail' Painkiller in Britain  Jul 10, 2006
...on the venom of a deadly sea snail was being launched in Britain today by Japanese drugmaker Eisai, which acquired the European rights to Prialt from Ireland's ... -International News Service

New nerve drug inspired by deadly snail  Jul 9, 2006
The treatment, called Prialt, is to be used to tackle persistent pain, such as that suffered by cancer patients and others in hospital with serious illnesses. ... -Scotsman

The deadly sea snail venom that will take away your pain  Jul 9, 2006
Prialt, or ziconotide, is the result of more than 20 years’ research by a scientist born in the Philippines, Baldomera Olivera, who is a professor at the ... -Times Online

Quest for Super Painkiller that Won't Addict  Jun 26, 2006
...world raced to make a drug. Initial efforts resulted in Prialt, which was modelled off the snail chemical. But the drug only works ... -TheTyee.ca

Pain Relief  Jul 13, 2006
...market in England. Prialt, a new painkiller based on the venom of a sea snail, is the result of more than 20 years of research. It is ... -Harrisonburg Daily News Record

PLEASE RELIEVE ME  Jul 13, 2006
...conventional drugs. Developed by Japanese scientists, Prialt is so potent that it's only used as a last resort for longterm pain. A ... -Mirror.co.uk

OXiGENE'S Board of Directors Names Experienced Biotech Executive ...  Jun 30, 2006
...are TNKase(TM) (for myocardial infarction), Raptiva(R) (for psoriasis), Xolair(R) (for asthma), Cathflo(R) (for catheter clearance) and Prialt(R) (for pain). ... -Genetic Engineering News

OXiGENE'S Board of Directors Names Experienced Biotech Executive ...  Jun 30, 2006
...are TNKase(TM) (for myocardial infarction), Raptiva(R) (forpsoriasis), Xolair(R) (for asthma), Cathflo(R) (for catheterclearance) and Prialt(R) (for pain). ... -Finanzen.net



Elan Reports First Quarter 2006 Financial Results  May 3, 2006
The 2006 net loss includes a gain of $44.2 million related to the sale of the Prialt(TM) European rights to Eisai Co., Ltd (Eisai) while the 2005 net loss ... - Business Wire

Elan's Q1 Net Loss Narrows On Higher Revenues, Margin Improvement ...  May 4, 2006
The current year quarter net loss included a gain of $44.2 million related to the sale of the European rights of painkiller Prialt to Eisai Co., Ltd, and share ... - Trading Markets





Elan Closes Prialt Rights Sale  Mar 20, 2006
Irish drug company Elan (ELN:NYSE ADR - commentary - research - Cramer's Take) said it completed the sale of the European rights to Prialt, a treatment for ... - TheStreet.com

Elan Closes Sale of Rights to Prialt In Europe to Eisai  Mar 20, 2006
Elan Corporation, plc today announced that it has completed the sale of the rights to Prialt(TM) (ziconotide, non-opioid severe chronic pain agent) in Europe ... - Genetic Engineering News

Elan Closes Sale of Rights to Prialt In Europe to Eisai  Mar 20, 2006
Elan Corporation, plc today announced that it hascompleted the sale of the rights to Prialt(TM) (ziconotide, non-opioidsevere chronic pain agent) in Europe to ... - Finanzen.net

Elan closes sale of rights to Prialt In Europe to Eisai  Mar 21, 2006
Irish drugs firm Elan Corporation, plc today announced that it has completed the sale of the rights to Prialt (ziconotide, non-opioid severe chronic pain agent ... - FinFacts Ireland

Elan completes Prialt Europe sale  Mar 21, 2006
Pharmaceutical company Elan has completed the sale of the marketing rights for its Prialt painkiller in Europe to Japanese company Eisai for up to $100m in cash ... - RTE.ie

Elan Closes Sale of Rights to Prialt In Europe to Eisai  Mar 20, 2006
DUBLIN, Ireland--(BUSINESS WIRE)--March 20, 2006--Elan Corporation, plc today announced that it has completed the sale of the rights to Prialt(TM) (ziconotide ... - Business Wire

Merck to Enter a Venture for Pain Drugs  Mar 19, 2006
The first drug that works by that mechanism, Prialt from the Elan Corporation, won Food and Drug Administration approval in December 2004 for use by patients ... - New York Times

Merck's New Pain Drugs  Mar 21, 2006
The first drug that works using the ion-blocking mechanism, Prialt from Elan, won US Food and Drug Administration approval in December 2004 for use by patients ... - International News Service

Elan drug European rights deal goes through  Mar 20, 2006
ISEQ-listed pharmaceutical Elan has completed the sale of the European rights to its chronic-pain drug Prialt to Eisai. Under the ... - Ireland Online

News In Brief  Mar 21, 2006
...overseas cover. DRUGMAKER Elan has completed the sale of the European rights of its chronic pain treatment Prialt to Eisai. ALLTRACEL ... - Irish Independent

Venomous snails aid medical science  Mar 26, 2006
Just over a year ago, the US Federal Drug Agency approved the first of a new type of painkiller - Prialt® - which can work in cases where ordinary drugs fail. ... - BBC News

Elan sells Prialt rights to Japanese firm  09 Feb 2006
By Ian Guider. ELAN has sold the European sales rights to its painkilling drug Prialt in a deal that could net the company €84 million. ... - IrishExaminer.com

ISEQ surges ahead  09 Feb 2006
Elan rose 30c to €12.20 today following news that it has agreed to sell the rights to its Prialt drug for the treatment of chronic pain in Europe to Eisai ... - Ireland Online

Elan to sell European rights of Prialt  09 Feb 2006
FEB. 9 2:17 PM ET Elan Corp. of Ireland announced Thursday it is selling the European rights of its chronic-pain drug Prialt to Eisai Co. Ltd. ... - BusinessWeek

Elan Corp. sells some Prialt rights  09 Feb 2006
FEB. 9 6:19 AM ET Elan Corp. of Ireland announced Thursday that it is selling the European rights of its chronic-pain drug Prialt to Eisai Co. Ltd. ... - BusinessWeek

UK Stocks Advance; FTSE 100 Has Biggest Gain in Three Months  09 Feb 2006
2.5 percent, to 12.2 euros. The company agreed to sell the European rights to its Prialt painkiller to Eisai Co. of Japan for as ... - Bloomberg

Elan and banks lead market gains  09 Feb 2006
...higher at €17.25. Elan surged ahead 30c to €12.20 after it sold its rights to Prialt in Europe. Greencore added 5c to €3.45. - Irish Examiner

11am Markets Update  09 Feb 2006
...were all stronger and Elan jumped 57 cent to €12.47 after it said it had sold its the European marketing rights to its painkiller drug Prialt to Japanese ... - RTE.ie

Elan meldt financiële resultaten vierde kwartaal en hele jaar ...  Jan 31, 2006
Revenue from Marketed Products 29.9 46.8 Maxipime(TM) 117.5 140.3 15.3 17.5 Azactam(TM) 50.6 57.7 6.4 (0.4) Tysabri 6.4 11.0 -- 2.0 Prialt(TM) -- 6.3 ... - Netherlands Corporate News (persbericht)

Loss Narrows for Elan  Jan 31, 2006
The increase of 28% was principally a result of higher sales of Maxipime and Azactam and revenue from Prialt, launched in 2005. ... - TheStreet.com

Losses at Elan improve to $384m and shares rise  Jan 31, 2006
A breakdown of last year's sales showed they were boosted by strong growth for Maxipime and Azactam, while its new pain treatment, Prialt, recorded sales of ... - Irish Independent

New drugs use saliva to help relieve pain  Jan 10, 2006
...about. Recently, new drugs have been added to the market, exenatides (Byetta/Amylin Lilly) and ziconotides (Prialt/Elan). These ... - Auburn Citizen

The wonders of creation  Jan 7, 2006
...meal. The chemical composition of the venom is now copied and we have Prialt, a drug that will spare humans unbearable pain. The ... - Manila Times

Bioprospectors raise ire as they patent more life forms  Jan 20, 2006
The venom of a deadly sea snail found off the coast of the Philippines led Elan Pharmaceuticals to develop the painkiller Prialt, which the Food and Drug ... - San Jose Mercury News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional